Moreover, studies on breast cancer cell line models have shown that constitutive activation of the NFκB pathway leads to downregulation of ER signaling [32], which can have a prominent role in tamoxifen resistance, if not in a generalized anti-hormonal therapy unresponsiveness. The gene discussed is NFKB1; the disease is breast carcinoma.